Table 1 FDA-approved EGFR TKIs
From: Emerging therapeutic agents for advanced non-small cell lung cancer
Drug | Month/year | Indication | Comments |
|---|---|---|---|
Erlotinib | May/2013 | 1st line metastatic EGFR mutant | First generation. Approved 18 November 2004 for 2nd-line metastatic NSCLC. 10 April 2010 maintenance |
Gefitinib | July/2015 | 1st line metastatic EGFR mutant patients | Approved in 2003 as third line, retracted approval 2005 |
Afatinib | July/2013 | 1st line metastatic EGFR mutant | Second generation |
January/2018 | 1st line metastatic EGFR non-resistant mutations | ||
Osimertinib | November/2015 | EGFR T790M mutation after progressed on EGFR TKI | Third generation. With CNS penetration |
April/2018 | 1st line metastatic EGFR mutant patients | ||
Dacomitinib | September/2018 | 1st line metastatic EGFR mutant patients | Second generation |